0.9% Physiological Saline

DRUG3 trials

Sponsors

Zurex Pharma, Inc., University Hospital Tuebingen

Conditions

Familial Mediterranean FeverSurgical Site Infection

Phase 1

Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

CompletedNCT02160587

Zurex Pharma, Inc.Surgical Site Infection

Start: 2014-07-31End: 2014-10-31Updated: 2015-03-17

Safety Study to Evaluate the Cumulative Irritation Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

CompletedNCT02160574

Zurex Pharma, Inc.Surgical Site Infection

Start: 2014-06-30End: 2014-09-30Updated: 2014-10-27

Phase 2

Tocilizumab for the Treatment of Familial Mediterranean Fever

CompletedNCT03446209

University Hospital TuebingenFamilial Mediterranean Fever

Start: 2018-04-23End: 2020-10-30Updated: 2020-11-18